This program will train post-residency MD's in;(1) the clinical, pathophysiologic.and pharmacologic aspects of neurologic diseases;( 2) the conceptualization, ethics, design, implementation, management, analysis and reporting of controlled clinical trials;and (3) population-based clinical research, including biostatistics and epidemiology. An integrated 2-3 year program provides;(1)preceptorial supervision by neuroscientists and biostatisticians who have extensive experience in clinical investigation and in development of novel therapies;(2)a customized curriculum of basic and applied statistics, neuro-epidemiology and computer science;(3)seminar programs on: clinical trial design;the basic sciences underlying experimental therapeutics;neuroethics, and grant and career development;(4)participation and collaboration with faculty from Neurology and Preventive &Community Medicine with expertise in outcome, cost-effectiveness, quality of life and other areas of health service research;(5)clinical experience in disease states under intensive investigation in Rochester and;(6)mentoring trainees in achieving an independent academic career. Training draws on strengths of 1) clinical neuroscientists with investigative programs in neuromuscular disease, movement disorders, multiple sclerosis, dementia, epilepsy, stroke, and AIDS;(2) integration with Biostatistics faculty;(3)formal teaching/research interactions with basic neuroscientists;(4) the resources of the Clinical Trials Coordination Centers in the Department of Neurology;and Rochester's CTS Institute. Trainees learn skills necessary to :( 1) generate new therapeutic knowledge applicable to neurologic disorders;(2) achieve independent professional growth and funding, and (3) obtain a tenure-track faculty position in a subspecialty of clinical neuroscience. Support is sought for 4 post-residency trainees accepting 2-4 trainees yearly into the program. Minority recruitment is emphasized. Training facilities include: the CTS Institute and Clinical Research Center, the Clinical Trials Coordination Centers, the Rare. Disease Network, Biostatistics Department, and three centers: Translational Neuromedicine;Neural Development and Disease;and Neurodegenerative and Vascular Brain Disorders.
Breakthroughs in neuroscience have provided new opportunities for the development of treatments for many neurological diseases including stroke, multiple sclerosis, neuromuscular disease, Parkinson's disease, and Alzheimer's disease. This program accepts 2-4 neurologists per year for training in the skills necessary to establish the benefit of novel therapies in clinical trials. Over 90% of 44 past trainees are now working in academic positions in 16 United States departments.
|Johnson, Nicholas E; Kaloides, Amy; Jones, Elaine (2016) Neurology Advocacy 2.0: After Sustainable Growth Rate Repeal. JAMA Neurol 73:151-2|
|Heatwole, Chad; Bode, Rita; Johnson, Nicholas E et al. (2016) Myotonic dystrophy health index: Correlations with clinical tests and patient function. Muscle Nerve 53:183-90|
|Salinas, Joel; Sprinkhuizen, Sara M; Ackerson, Teri et al. (2016) An International Standard Set of Patient-Centered Outcome Measures After Stroke. Stroke 47:180-6|
|Johnson, Nicholas E; Ekstrom, Anne-Berit; Campbell, Craig et al. (2016) Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy. Dev Med Child Neurol 58:698-705|
|Bednasz, Cindy; Luque, Amneris E; Zingman, Barry S et al. (2016) Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. Curr Vasc Pharmacol 14:280-7|
|Bellizzi, Matthew J; Geathers, Jasmine S; Allan, Kevin C et al. (2016) Platelet-Activating Factor Receptors Mediate Excitatory Postsynaptic Hippocampal Injury in Experimental Autoimmune Encephalomyelitis. J Neurosci 36:1336-46|
|Rowe, Ian A; Tully, Damien C; Armstrong, Matthew J et al. (2016) Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 22:287-97|
|Statland, Jeffrey M; Heatwole, Chad; Eichinger, Katy et al. (2016) Electrical impedance myography in facioscapulohumeral muscular dystrophy. Muscle Nerve 54:696-701|
|Damania, D; Kung, N T-M; Jain, M et al. (2016) Factors associated with recurrent stroke and recanalization in patients presenting with isolated symptomatic carotid occlusion. Eur J Neurol 23:127-32|
|Tawil, Rabi; Kissel, John T; Heatwole, Chad et al. (2015) Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Is Neurology 85:357-64|
Showing the most recent 10 out of 77 publications